Vanguard Asset Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Vanguard Asset Management's MLYS Position: Q3 2026 in Review
Vanguard Asset Management increased its Mineralys Therapeutics (MLYS) stake by 16% in Q3 2026, buying an estimated $165K and bringing the position to 45,261 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1801.
Vanguard Asset Management first reported a position in MLYS in Q1 2026 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Vanguard Asset Management held 45,261 shares of Mineralys Therapeutics worth $1.14M as of Q3 2026.
- Vanguard Asset Management bought 6,074 Mineralys Therapeutics shares in Q3 2026, an estimated $165K.
- Mineralys Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1801 holding.
- Vanguard Asset Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.